The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Anti–TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy
Open accessAbstract
TGF- β has been implicated as a major pathogenic factor in diabetic nephropathy. This randomized, double-blind, phase 2 study assessed whether modulating TGF- β 1 activity with a TGF- β 1–specific, humanized, neutralizing monoclonal antibody (TGF- β 1 mAb) is safe and more effective than placebo in slowing renal function loss in patients with diabetic nephropathy on chronic stable renin-angiotensin system inhibitor treatment. We randomized 416 patients aged ≥25 years with type 1 or type 2 diabetes, a serum creatinine (SCr) level of 1.3–3.3 mg/dl for women and 1.5–3.5 mg/dl for men (or eGFR of 20–60 ml/min per 1.73 m 2 ), and a 24-hour urine protein-to-creatinine ratio ≥800 mg/g to TGF- β 1 mAb (2-, 10-, or 50-mg monthly subcutaneous dosing for 12 months) or placebo. We assessed a change in SCr from baseline to 12 months as the primary efficacy variable. Although the Data Monitoring Committee did not identify safety issues, we terminated the trial 4 months early for futility on the basis of their recommendation. The placebo group had a mean±SD change in SCr from baseline to end of treatment of 0.33±0.67 mg/dl. Least squares mean percentage change in SCr from baseline to end of treatment did not differ between placebo (14%; 95% confidence interval [95% CI], 9.7% to 18.2%) and TGF- β 1 mAb treatments (20% [95% CI, 15.3% to 24.3%], 19% [95% CI, 14.2% to 23.0%], and 19% [95% CI, 14.0% to 23.3%] for 2-, 10-, and 50-mg doses, respectively). Thus, TGF- β 1 mAb added to renin-angiotensin system inhibitors did not slow progression of diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Massagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Self-citationLevey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Self-citationMassagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Diagnosis and Classification of diabetes mellitus
(2014) · Diapedia · doi:10.14496/dia..20 · Cited by 3,214
(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.73 · Cited by 3,206
Transforming Growth Factor β in Tissue Fibrosis
Epstein, F. H., Border, W. A., & Noble, N. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311907 · Cited by 3,069
US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States
Saran, R., Robinson, B., Abbott, K. C., Agodoa, L. Y. C., Albertus, P., Ayanian, J., Balkrishnan, R., Bragg-Gresham, J., Cao, J., Chen, J. L. T., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.12.004 · Cited by 2,191
Hu, F. B. (2011) · Diabetes Care · doi:10.2337/dc11-0442 · Cited by 1,954
Plasma aldosterone regulation in anephric man
Walker, W. G., & Cooke, C. R. (1973) · Kidney International · doi:10.1038/ki.1973.1 · Cited by 1,841
Changes in diabetes-related complications in the United States, 1990-2010
Gregg, E. W., Li, Y., Wang, J., Rios Burrows, N., Ali, M. K., Rolka, D., Williams, D. E., & Geiss, L. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310799 · Cited by 1,749
Signal Transduction by the TGF-β Superfamily
Attisano, L., & Wrana, J. L. (2002) · Science · doi:10.1126/science.1071809 · Cited by 1,268
Temporal trends in the prevalence of diabetic kidney disease in the United States
de Boer, I. H. (2011) · JAMA · doi:10.1001/jama.2011.861 · Cited by 1,036
Gao, X., Wu, G., Gu, X., Fu, L., & Mei, C. (2013) · Kidney and Blood Pressure Research · doi:10.1159/000355743 · Cited by 1,035
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1
Border, W. A., Okuda, S., Languino, L. R., Sporn, M. B., & Ruoslahti, E. (1990) · Nature · doi:10.1038/346371a0 · Cited by 988
Ziyadeh, F. N., Hoffman, B. B., Han, D. C., Iglesias-de la Cruz, M. C., Hong, S. W., Isono, M., Chen, S., McGowan, T. A., & Sharma, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120055097 · Cited by 907
US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States
Saran, R., Li, Y., Robinson, B., Ayanian, J., Balkrishnan, R., Bragg-Gresham, J., Chen, J. T. L., Cope, E., Gipson, D., He, K., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.05.001 · Cited by 656
Levey, A. S., Inker, L. A., Matsushita, K., Greene, T., Willis, K., Lewis, E., de Zeeuw, D., Cheung, A. K., & Coresh, J. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.07.030 · Cited by 620
Self-citationTGF-β and fibrosis in different organs — molecular pathway imprints
Pohlers, D., Brenmoehl, J., Löffler, I., Müller, C. K., Leipner, C., Schultze-Mosgau, S., Stallmach, A., Kinne, R. W., & Wolf, G. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.06.004 · Cited by 576
Okuda, S., Languino, L. R., Ruoslahti, E., & Border, W. A. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114731 · Cited by 546
Divergence and convergence of TGF‐β/BMP signaling
Miyazono, K., Kusanagi, K., & Inoue, H. (2001) · Journal of Cellular Physiology · doi:10.1002/jcp.1080 · Cited by 505
Mediators of Diabetic Renal Disease: The Case for TGF-β as the Major Mediator
Ziyadeh, F. N. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000093460.24823.5b · Cited by 463
Expression of transforming growth factor-β isoforms in human glomerular diseases
Yamamoto, T., Noble, N. A., Cohen, A. H., Nast, C. C., Hishida, A., Gold, L. I., & Border, W. A. (1996) · Kidney International · doi:10.1038/ki.1996.65 · Cited by 418
TGF-β in Renal Injury and Disease
Böttinger, E. P. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.02.009 · Cited by 339
Pirfenidone for Diabetic Nephropathy
Sharma, K., Ix, J. H., Mathew, A. V., Cho, M., Pflueger, A., Dunn, S. R., Francos, B., Sharma, S., Falkner, B., McGowan, T. A., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010101049 · Cited by 319
Increased Renal Production of Transforming Growth Factor-β1 in Patients with Type II Diabetes
Sharma, K., Ziyadeh, F. N., Alzahabi, B., McGowan, T. A., Kapoor, S., Kurnik, B. R. C., Kurnik, P. B., & Weisberg, L. S. (1997) · Diabetes · doi:10.2337/diab.46.5.854 · Cited by 274
Trachtman, H., Fervenza, F. C., Gipson, D. S., Heering, P., Jayne, D. R. W., Peters, H., Rota, S., Remuzzi, G., Rump, L. C., Sellin, L. K., et al. (2011) · Kidney International · doi:10.1038/ki.2011.33 · Cited by 263
TGF-β isoforms in renal fibrogenesis
Yu, L., Border, W. A., Huang, Y., & Noble, N. A. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00162.x · Cited by 176
The Gap between Estimated Incidence of End-Stage Renal Disease and Use of Therapy
Anand, S., Bitton, A., & Gaziano, T. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072860 · Cited by 168
Sharma, K., Eltayeb, B. O., McGowan, T. A., Dunn, S. R., Alzahabi, B., Rohde, R., Ziyadeh, F. N., & Lewis, E. J. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70037-5 · Cited by 161
Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in db/db mice
Chen, S., de la Cruz, M. D. C. I., Jim, B., Hong, S. W., Isono, M., & Ziyadeh, F. N. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02708-0 · Cited by 137
Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-β levels
Agarwal, R., Siva, S., Dunn, S., & Sharma, K. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.31392 · Cited by 109
Combining TGF-β inhibition and angiotensin II blockade results in enhanced antifibrotic effect
Yu, L. H., Border, W. A., Anderson, I., Mccourt, M., Huang, Y., & Noble, N. A. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00901.x · Cited by 95
Gassman, J., Greene, T., Wright, J. T., Agodoa, L. Y. C., Bakris, G. L., Beck, G. J., Douglas, J. G., Jamerson, K., Lewis, J. B., Kutner, M., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000070080.21680.cb · Cited by 94
Self-citationMa, L.-J., Jha, S. S., Ling, H., Pozzi, A., Ledbetter, S., & Fogo, A. B. (2003) · Kidney International · doi:10.1111/j.1523-1755.2004.00381.x · Cited by 88
Benigni, A., Zoja, C., Campana, M., et al. (2006) · Nephron Experimental Nephrology · doi:10.1159/000094967 · Cited by 46
Cited by
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
Ferrucci, L., & Fabbri, E. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0064-2 · Cited by 3,690
Transforming growth factor–β in tissue fibrosis
Frangogiannis, N. G. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190103 · Cited by 1,278
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Targeting the progression of chronic kidney disease
Ruiz-Ortega, M., Rayego-Mateos, S., Lamas, S., Ortiz, A., & Rodrigues-Diez, R. R. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0248-y · Cited by 979
CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease
Anders, H.-J., Huber, T. B., Isermann, B., & Schiffer, M. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0001-y · Cited by 796
Metadata
- Authors
- Voelker, J., Berg, P. H., Sheetz, M., Duffin, K., Shen, T., Moser, B., Greene, T., Blumenthal, S. S., Rychlik, I., Yagil, Y., Zaoui, P., & Lewis, J. B.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2016-09-19
- Volume
- 28
- Issue
- 3
- Pages
- 953-962
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W2521123529
- Cited by
- 275
- References
- 41
- FWCI
- 18.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.